The frequency and VEN analysis of medical prescriptions for patients with duodenal ulcer disease in healthcare institutions

Aim. To perform the frequency and VEN analysis of medical prescriptions for patients with duodenal ulcer disease (DUD) in a healthcare institution. Materials and methods. Depersonalized information base containing data from 112 histories of patients with DUD who were treated in one of the healthcare institutions in Vinnytsia, prescription sheets, the National List of Essential Medicines, the Unified Clinical Protocol of Primary and Specialized Medical Care “Peptic ulcer of the stomach and duodenal ulcer in adults and children” (2023), the State Formulary of Medicines (2023) were used. Research methods such as retrospective, system-analytical, frequency and VEN analysis were applied. Results. As a result of the frequency and VEN analysis conducted during the study period, doctors prescribed a total of 48 active substances by INN and 109 drugs by trade names (TN). A total of 817 drugs were prescribed by TN. According to the results of this analysis, it was found that the largest number of prescriptions fell on proton pump inhibitors of different generations (21.3 % of all prescriptions) and multienzyme drugs (15.06 % of all prescriptions). For the eradication of Helicobacter pylori, agents for the treatment of peptic ulcer and gastroesophageal reflux disease, combinations for the eradication of Helicobacter pylori were prescribed (14.89 % of all prescriptions). There were also many prescriptions from groups of drugs affecting the digestive system (13.89 %). For the treatment of concomitant pathologies, drugs used to treat the liver and biliary tract (4.28 %), intestinal anti-inflammatory drugs (2.08 %), anti-anemic drugs (1.46 %), antibacterial drugs, antibiotics, hypolipidemic, hypnotic, sedative drugs, antidepressants, etc., were prescribed. It was proved that the main of pharmacotherapy of DUD was etiological and pathogenetic therapy. According to the VEN analysis, 8 drugs (17 %) were included in category V, 22 drugs (46 %) – in category E, and 18 drugs (37 %) – in category N, out of 48 drugs by INN. Conclusions. Therefore, the study conducted showed that a significant number of prescriptions and financial resources were directed to the use of secondary drugs that were not included in the regulatory legal acts regulating the pharmaceutical provision of patients with DUD.